The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation

Diabetologia

Volumn 43, Issue 5, 2000, Pages 660-664

  Cooper, M E ^a   Thallas, V ^a   Forbes, J ^a   Scalbert, E ^b   Sastra, S ^a   Darby, I ^c   Soulis, T ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b IRIS Institut de Recherches Internationales Servier   (France)

^c RMIT UNIVERSITY   (Australia)

Author keywords

Cross link breaker; Glycation; Thiazolium; Vascular

Indexed keywords

ADVANCED GLYCATION END PRODUCT; N PHENACYLTHIAZOLIUM BROMIDE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CROSS LINKING; DIABETES MELLITUS; DIABETIC ANGIOPATHY; IMMUNOHISTOCHEMISTRY; MALE; MESENTERY BLOOD VESSEL; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; STREPTOZOCIN DIABETES; VASCULAR DISEASE;

ANIMALS; BLOOD PRESSURE; BLOOD VESSELS; DIABETES MELLITUS, EXPERIMENTAL; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; IMMUNOHISTOCHEMISTRY; MALE; RATS; RATS, SPRAGUE-DAWLEY; SPLANCHNIC CIRCULATION; THIAZOLES;

EID: 0034027831     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051355     Document Type: Article

References (15)

1. 1. Brownlee M (1994) Lilly Lecture 1993. Glycation and diabetic complications. Diabetes 43: 836-841
2. 2. Rumble JR, Cooper ME, Soulis T et al. (1997) Vascular hypertrophy in experimental diabetes: role of advanced glycation end products. J Clin Invest 99: 1016-1027
3. 3. Corbett JA, Tilton RG, Chang K et al. (1992) Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 41: 552-556
4. 4. Vasan S, Zhang X, Zhang X et al. (1996) An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 382: 275-278
5. 5. Cooper M, Rumble J, Komers R, Du H, Jandeleit K, Chou S (1994) Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition. Diabetes 43: 1221-1228
6. 6. Soulis T, Sastra S, Thallas V et al. (1999) A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes. Diabetologia 42: 472-479
7. 7. Bunag R (1973) Validation in awake rats of a tail-cuff method for measuring systolic pressure. J Appl Physiol 34: 279-282
8. 8. Soulis T, Cooper ME, Sastra S et al. (1997) Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats. Diabetologia 40: 1141-1151
9. 9. Schwedler S, Verbeke P, Bakala H et al. (1998) N-Phenacylthiazolium bromide (PTB) decreases renal AGE levels and increases urinary AGE excretion, without ameliorating diabetic nephropathy in C57BL/6 mice. J Am Soc Nephrol 9: 641A (Abstract)
10. 10. Youssef S, Nguyen DT, Soulis T, Panagiotopoulos S, Jerums G, Cooper ME (1999) Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding. Kidney Int 55: 907-916
11. 11. Gugliucci A, Bendayan M (1996) Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 39: 149-160
12. 12. Wolffenbuttel BHR, Boulanger CM, Crijns FRL et al. (1998) Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA 95: 4630-4634
13. 13. Rumble JR, Gilbert RE, Cox A, Wu L, Cooper ME (1998) Angiotensin converting enzyme inhibition reduces the expression of transforming growth factor-beta(1) and type IV collagen in diabetic vasculopathy. J Hypertens 16: 1603-1609
14. 14. Hogan M, Cerami A, Bucala R (1992) Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. J Clin Invest 90: 1110-1115
15. 15. Huijberts MS, Wolffenbuttel BH, Boudier HA et al. (1993) Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J Clin Invest 92: 1407-1411